Selected research
Market Analysis & Forecast
Global Genetic Disease Diagnostic Market Analysis and Forecast 2026-2032
Market perspective
The global Genetic Disease Diagnostic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Genetic Disease Diagnostic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Genetic Disease Diagnostic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Genetic Disease Diagnostic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Genetic Disease Diagnostic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Genetic Disease Diagnostic include Abbott, PerkinElmer, Roche Diagnostics, Bio Rad, Thermo Fisher Scientific, BGI Group, Berry Genomics, Da An Gene Co., Ltd. and Illumina, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Genetic Disease Diagnostic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Genetic Disease Diagnostic, also provides the revenue of main regions and countries. Of the upcoming market potential for Genetic Disease Diagnostic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Genetic Disease Diagnostic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Genetic Disease Diagnostic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Genetic Disease Diagnostic revenue, projected growth trends, production technology, application and end-user industry.
Genetic Disease Diagnostic Segment by Company
Abbott
PerkinElmer
Roche Diagnostics
Bio Rad
Thermo Fisher Scientific
BGI Group
Berry Genomics
Da An Gene Co., Ltd.
Illumina
CapitalBio Technology
Genetic Disease Diagnostic Segment by Type
Prenatal Diagnosis
Screening for Single Gene Genetic Disease
Preimplantation Genetic Testing
Others
Genetic Disease Diagnostic Segment by Application
Hospital
Medical Laboratory
Others
Genetic Disease Diagnostic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Disease Diagnostic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Genetic Disease Diagnostic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Disease Diagnostic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Genetic Disease Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Genetic Disease Diagnostic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genetic Disease Diagnostic revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prenatal Diagnosis
- Screening for Single Gene Genetic Disease
- Preimplantation Genetic Testing
- Others
Applications
- Hospital
- Medical Laboratory
- Others
Companies covered
- Abbott
- PerkinElmer
- Roche Diagnostics
- Bio Rad
- Thermo Fisher Scientific
- BGI Group
- Berry Genomics
- Da An Gene Co., Ltd.
- Illumina
- CapitalBio Technology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Genetic Disease Diagnostic Market by Type
- 1.2.1 Global Genetic Disease Diagnostic Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Prenatal Diagnosis
- 1.2.3 Screening for Single Gene Genetic Disease
- 1.2.4 Preimplantation Genetic Testing
- 1.2.5 Others
- 1.3 Genetic Disease Diagnostic Market by Application
- 1.3.1 Global Genetic Disease Diagnostic Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Medical Laboratory
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Genetic Disease Diagnostic Market Dynamics
- 2.1 Genetic Disease Diagnostic Industry Trends
- 2.2 Genetic Disease Diagnostic Industry Drivers
- 2.3 Genetic Disease Diagnostic Industry Opportunities and Challenges
- 2.4 Genetic Disease Diagnostic Industry Restraints
3 Global Growth Perspective
- 3.1 Global Genetic Disease Diagnostic Market Perspective (2021-2032)
- 3.2 Global Genetic Disease Diagnostic Growth Trends by Region
- 3.2.1 Global Genetic Disease Diagnostic Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Genetic Disease Diagnostic Market Size by Region (2021-2026)
- 3.2.3 Global Genetic Disease Diagnostic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Genetic Disease Diagnostic Revenue by Players
- 4.1.1 Global Genetic Disease Diagnostic Revenue by Players (2021-2026)
- 4.1.2 Global Genetic Disease Diagnostic Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Genetic Disease Diagnostic Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Genetic Disease Diagnostic Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Genetic Disease Diagnostic Key Players Headquarters & Area Served
- 4.4 Global Genetic Disease Diagnostic Players, Product Type & Application
- 4.5 Global Genetic Disease Diagnostic Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Genetic Disease Diagnostic Market CR5 and HHI
- 4.6.3 2025 Genetic Disease Diagnostic Tier 1, Tier 2, and Tier 3
5 Genetic Disease Diagnostic Market Size by Type
- 5.1 Global Genetic Disease Diagnostic Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 5.3 Global Genetic Disease Diagnostic Revenue Market Share by Type (2021-2032)
6 Genetic Disease Diagnostic Market Size by Application
- 6.1 Global Genetic Disease Diagnostic Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 6.3 Global Genetic Disease Diagnostic Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Abbott
- 7.1.1 Abbott Company Information
- 7.1.2 Abbott Business Overview
- 7.1.3 Abbott Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.1.4 Abbott Genetic Disease Diagnostic Product Portfolio
- 7.1.5 Abbott Recent Developments
- 7.2 PerkinElmer
- 7.2.1 PerkinElmer Company Information
- 7.2.2 PerkinElmer Business Overview
- 7.2.3 PerkinElmer Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.2.4 PerkinElmer Genetic Disease Diagnostic Product Portfolio
- 7.2.5 PerkinElmer Recent Developments
- 7.3 Roche Diagnostics
- 7.3.1 Roche Diagnostics Company Information
- 7.3.2 Roche Diagnostics Business Overview
- 7.3.3 Roche Diagnostics Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.3.4 Roche Diagnostics Genetic Disease Diagnostic Product Portfolio
- 7.3.5 Roche Diagnostics Recent Developments
- 7.4 Bio Rad
- 7.4.1 Bio Rad Company Information
- 7.4.2 Bio Rad Business Overview
- 7.4.3 Bio Rad Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.4.4 Bio Rad Genetic Disease Diagnostic Product Portfolio
- 7.4.5 Bio Rad Recent Developments
- 7.5 Thermo Fisher Scientific
- 7.5.1 Thermo Fisher Scientific Company Information
- 7.5.2 Thermo Fisher Scientific Business Overview
- 7.5.3 Thermo Fisher Scientific Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.5.4 Thermo Fisher Scientific Genetic Disease Diagnostic Product Portfolio
- 7.5.5 Thermo Fisher Scientific Recent Developments
- 7.6 BGI Group
- 7.6.1 BGI Group Company Information
- 7.6.2 BGI Group Business Overview
- 7.6.3 BGI Group Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.6.4 BGI Group Genetic Disease Diagnostic Product Portfolio
- 7.6.5 BGI Group Recent Developments
- 7.7 Berry Genomics
- 7.7.1 Berry Genomics Company Information
- 7.7.2 Berry Genomics Business Overview
- 7.7.3 Berry Genomics Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.7.4 Berry Genomics Genetic Disease Diagnostic Product Portfolio
- 7.7.5 Berry Genomics Recent Developments
- 7.8 Da An Gene Co., Ltd.
- 7.8.1 Da An Gene Co., Ltd. Company Information
- 7.8.2 Da An Gene Co., Ltd. Business Overview
- 7.8.3 Da An Gene Co., Ltd. Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.8.4 Da An Gene Co., Ltd. Genetic Disease Diagnostic Product Portfolio
- 7.8.5 Da An Gene Co., Ltd. Recent Developments
- 7.9 Illumina
- 7.9.1 Illumina Company Information
- 7.9.2 Illumina Business Overview
- 7.9.3 Illumina Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.9.4 Illumina Genetic Disease Diagnostic Product Portfolio
- 7.9.5 Illumina Recent Developments
- 7.10 CapitalBio Technology
- 7.10.1 CapitalBio Technology Company Information
- 7.10.2 CapitalBio Technology Business Overview
- 7.10.3 CapitalBio Technology Genetic Disease Diagnostic Revenue and Gross Margin (2021-2026)
- 7.10.4 CapitalBio Technology Genetic Disease Diagnostic Product Portfolio
- 7.10.5 CapitalBio Technology Recent Developments
8 North America
- 8.1 North America Genetic Disease Diagnostic Revenue (2021-2032)
- 8.2 North America Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 8.2.1 North America Genetic Disease Diagnostic Revenue by Type (2021-2026)
- 8.2.2 North America Genetic Disease Diagnostic Revenue by Type (2027-2032)
- 8.3 North America Genetic Disease Diagnostic Revenue Share by Type (2021-2032)
- 8.4 North America Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 8.4.1 North America Genetic Disease Diagnostic Revenue by Application (2021-2026)
- 8.4.2 North America Genetic Disease Diagnostic Revenue by Application (2027-2032)
- 8.5 North America Genetic Disease Diagnostic Revenue Share by Application (2021-2032)
- 8.6 North America Genetic Disease Diagnostic Revenue by Country
- 8.6.1 North America Genetic Disease Diagnostic Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Genetic Disease Diagnostic Revenue by Country (2021-2026)
- 8.6.3 North America Genetic Disease Diagnostic Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Genetic Disease Diagnostic Revenue (2021-2032)
- 9.2 Europe Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 9.2.1 Europe Genetic Disease Diagnostic Revenue by Type (2021-2026)
- 9.2.2 Europe Genetic Disease Diagnostic Revenue by Type (2027-2032)
- 9.3 Europe Genetic Disease Diagnostic Revenue Share by Type (2021-2032)
- 9.4 Europe Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 9.4.1 Europe Genetic Disease Diagnostic Revenue by Application (2021-2026)
- 9.4.2 Europe Genetic Disease Diagnostic Revenue by Application (2027-2032)
- 9.5 Europe Genetic Disease Diagnostic Revenue Share by Application (2021-2032)
- 9.6 Europe Genetic Disease Diagnostic Revenue by Country
- 9.6.1 Europe Genetic Disease Diagnostic Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Genetic Disease Diagnostic Revenue by Country (2021-2026)
- 9.6.3 Europe Genetic Disease Diagnostic Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Genetic Disease Diagnostic Revenue (2021-2032)
- 10.2 China Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 10.2.1 China Genetic Disease Diagnostic Revenue by Type (2021-2026)
- 10.2.2 China Genetic Disease Diagnostic Revenue by Type (2027-2032)
- 10.3 China Genetic Disease Diagnostic Revenue Share by Type (2021-2032)
- 10.4 China Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 10.4.1 China Genetic Disease Diagnostic Revenue by Application (2021-2026)
- 10.4.2 China Genetic Disease Diagnostic Revenue by Application (2027-2032)
- 10.5 China Genetic Disease Diagnostic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Genetic Disease Diagnostic Revenue (2021-2032)
- 11.2 Asia Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 11.2.1 Asia Genetic Disease Diagnostic Revenue by Type (2021-2026)
- 11.2.2 Asia Genetic Disease Diagnostic Revenue by Type (2027-2032)
- 11.3 Asia Genetic Disease Diagnostic Revenue Share by Type (2021-2032)
- 11.4 Asia Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 11.4.1 Asia Genetic Disease Diagnostic Revenue by Application (2021-2026)
- 11.4.2 Asia Genetic Disease Diagnostic Revenue by Application (2027-2032)
- 11.5 Asia Genetic Disease Diagnostic Revenue Share by Application (2021-2032)
- 11.6 Asia Genetic Disease Diagnostic Revenue by Country
- 11.6.1 Asia Genetic Disease Diagnostic Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Genetic Disease Diagnostic Revenue by Country (2021-2026)
- 11.6.3 Asia Genetic Disease Diagnostic Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Genetic Disease Diagnostic Revenue (2021-2032)
- 12.2 SAMEA Genetic Disease Diagnostic Revenue by Type (2021-2032)
- 12.2.1 SAMEA Genetic Disease Diagnostic Revenue by Type (2021-2026)
- 12.2.2 SAMEA Genetic Disease Diagnostic Revenue by Type (2027-2032)
- 12.3 SAMEA Genetic Disease Diagnostic Revenue Share by Type (2021-2032)
- 12.4 SAMEA Genetic Disease Diagnostic Revenue by Application (2021-2032)
- 12.4.1 SAMEA Genetic Disease Diagnostic Revenue by Application (2021-2026)
- 12.4.2 SAMEA Genetic Disease Diagnostic Revenue by Application (2027-2032)
- 12.5 SAMEA Genetic Disease Diagnostic Revenue Share by Application (2021-2032)
- 12.6 SAMEA Genetic Disease Diagnostic Revenue by Country
- 12.6.1 SAMEA Genetic Disease Diagnostic Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Genetic Disease Diagnostic Revenue by Country (2021-2026)
- 12.6.3 SAMEA Genetic Disease Diagnostic Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst